– USA, MA – Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the appointment of James Huang to its Board of Directors. Mr. Huang is currently a Managing Partner at Kleiner Perkins Caufield & Byers China and has founded and financed several innovative life sciences companies, including GenScript, Legend Biotech and Zai Lab. He is also Founding Partner of Panacea Venture, which formed TriArm Therapeutics, the funding partner for Ziopharm’s joint venture, Eden BioCell.
“We are delighted to welcome James to Ziopharm’s Board of Directors. He has an unparalleled track record of success in creating and building value with life science companies in and around China,” said CEO, Dr Laurence Cooper. “James shares our vision for harnessing the power of the non-viral Sleeping Beauty system to commercialize novel treatments for cancer, and his vision and business acumen have been instrumental to the formation and rapid progress of our Eden BioCell joint venture. We look forward to adding his deep experience and perspective as a valuable resource to our Board.”
About James Huang
Mr. Huang joined KPCB China as a Managing Partner in 2011 and focused on the firm’s life sciences practice. Prior to joining KPCB, he was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, he led numerous investments in China. Prior to joining Vivo in 2007, Mr. Huang was President of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, Mr. Huang held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp (acquired by Johnson & Johnson). Mr. Huang also built GenScript, including Legend Biotech from a small U.S. venture-backed company into a revenue-generating company with a multi-billion valuation on the Hong Kong Stock Exchange and Nasdaq.
Mr. Huang added, “My career focus has been to identify the best potential technology platforms for investment and to develop those I believe can reach the most patients. We have long sought to identify a viable solution to the problems of cost and manufacturing complexity in the CAR-T space. I believe that Ziopharm’s approach, with its non-viral DNA plasmid-based Sleeping Beauty platform, has the best chance to stand apart from the competition to solve these issues. I am delighted to join Ziopharm’s Board of Directors and look forward to working with Laurence and the experienced Ziopharm team.”
About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost-effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals.
For more information: https://ziopharm.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.